RDHLNasdaqPharmaceutical Preparations
RedHill Biopharma Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026
$0.50+0.02 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
–
Operating margin
-2776.9%−2678.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -96.4% | -83.3% | -66.2% | +57.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 12.66 | 0.96 | 0.34 | |
| Interest coverage | -81.4× | -5.0× | -5.5× | |
| Inventory turnover | – | 8.8× | – | |
| Capex to revenue | 84.2% | 0.6% | 1.7% | |
| Diluted shares | 129M | 364M | 31.59B |
Where the cash went
Fiscal 2021 to 2025, five years combined
RedHill Biopharma generated $149.07M from operations and spent $338.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$149.07M
Used
$338.00K
Capital expenditure$338.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 4 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$9.65M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$9.65M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.54 → 0.34
- No dilutionShare count did not rise12.32B → 31.59B
- Gross margin improvedGross margin up on the prior year60.31% → –
- More efficientAsset turnover rose0.35 → 0.02